Telemedicine – the standalone study that became the new normal Telemedicine – the standalone study that became the new normal Dr Vijay Prabhakar tells us how a remote healing project made him a pandemic pioneer.Read it now!
Translational Medicine & Clinical Pharmacology Translational Medicine & Clinical Pharmacology We connect the right patient with the right drug on the right dosing schedule using data science methods from pharmacometrics to systems pharmacology.
On two wheels for more animal health On two wheels for more animal health Cowtribe’s social entrepreneurs win Boehringer Ingelheim's Accelerator Program.
Boehringer Ingelheim Access to Healthcare Strategy last mile Boehringer Ingelheim Access to Healthcare Strategy last mile We aspire to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world.
EMA filing acceptance and validation for spesolimab EMA filing acceptance and validation for spesolimab The European Medicines Agency has accepted and validated the marketing authorization application for spesolimab in generalized pustular psoriasis
Boehringer expands production site in Greece Boehringer expands production site in Greece Boehringer expands production site in Greece for new medicine
Distributing medicine globally with pharmaceutical logistics Distributing medicine globally with pharmaceutical logistics From Germany to Australia, here’s what it takes from operations and logistics to ensure patients get their medicine on time, every time.
European Metacam® indication expanded to guinea pigs European Metacam® indication expanded to guinea pigs Boehringer Ingelheim adds a new species to its Metacam® brand in Europe, expanding the indications of this widely-used medicine to guinea pigs.
Interview Dr Mehdi Shahidi Interview Dr Mehdi Shahidi Interview with Dr Mehdi Shahidi, Chief Medical Officer and Head of the Corporate Division Medicine at Boehringer Ingelheim
university-of-medical-excellence-harvard university-of-medical-excellence-harvard A program designed by Harvard Medical School Executive Education with the goal of accelerating clinical development and medical affairs
Arti-cell Forte stem cell-based veterinary product Arti-cell Forte stem cell-based veterinary product Boehringer Ingelheim launches the first-ever registered stem cell-based veterinary medicine
Boehringer Ingelheim reaches more patients than ever, innovation drives growth Boehringer Ingelheim reaches more patients than ever, innovation drives growth Boehringer Ingelheim reports a strong performance in 2022.
NEJM-IL-36-Phase-1-GPP-data NEJM-IL-36-Phase-1-GPP-data Data published in The New England Journal of Medicine show rapid improvement of symptoms in patients with a rare form of pustular psoriasis
STOP Rabies: moving towards elimination STOP Rabies: moving towards elimination Rabies still kills thousands of people every year. However, rabies is 100 percent vaccine preventable. We contribute to eliminating the disease.
BI X colleague about working with purpose BI X colleague about working with purpose Ding works on an app that gives patients remote access to stroke rehabilitation via their mobile phones and tablets
FDA Grants Breakthrough Status to Schizophrenia Treatment FDA Grants Breakthrough Status to Schizophrenia Treatment Boehringer Ingelheim and Click Therapeutics receive FDA Breakthrough Device Designation for schizophrenia prescription digital therapeutic
Access to Healthcare: How we help underserved communities Access to Healthcare: How we help underserved communities Access to healthcare is not a given for everyone. We are partnering with an organization in Rome to help underserved communities.
Advancing health equity for rural doctors in Mexico Advancing health equity for rural doctors in Mexico Our virtual sales team helps doctors stay informed through digital education about the latest treatments, regardless of their location
BIVF funding more than doubled to 250 M€ BIVF funding more than doubled to 250 M€ Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million
Boehringer Ingelheim and GST prepared bring innovation to equine market Boehringer Ingelheim and GST prepared bring innovation to equine market Boehringer Ingelheim and Global Stem Cell Technology are prepared to bring groundbreaking innovation to equine market
commitments to sustainable development commitments to sustainable development On One Health Day, Boehringer Ingelheim shares an update on its strategic approach to sustainability for employees, partners and wider communities
Drug Discovery at Boehringer Ingelheim Drug Discovery at Boehringer Ingelheim Find out more about the drug discovery process at Boehringer Ingelheim
Veterinarians go beyond: animal care and veterinary medicine Veterinarians go beyond: animal care and veterinary medicine We surveyed over 1000 veterinarians from six countries. Did you know that only 49% of respondents think that the veterinary profession is appreciated?
Agreement-to-acquire-Labor-Dr.-Merk Agreement-to-acquire-Labor-Dr.-Merk Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen to strengthen its next generation cancer immunology program
A beginner’s guide to fighting off cat parasites A beginner’s guide to fighting off cat parasites Prof. Donato Traversa explains the risk of multiparasitic infections and/or infestations in cats